Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: A gynecologic oncology group study

Journal of Clinical Oncology

Volumn 18, Issue 16, 2000, Pages 2957-2962

  Rose, Peter G ^a   Rodriguez, Michael ^a   Waggoner, Steven ^a   Greer, Benjamin E ^a   Horowitz, Ira R ^a   Fowler, Jeffrey M ^a   McGuire, William P ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; OVARY CARCINOMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

EID: 0033883896     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.16.2957     Document Type: Article

References (32)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
3. Oral etoposide is active against platinum-resistant epithelial ovarian cancer
4. Protracted oral etoposide in epithelial ovarian cancer: A phase II study in patients with relapsed or platinum resistant disease
5. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study
6. Sequence-dependent cytotoxicity of etoposide and paclitaxel in human breast and lung cancer cell lines
7. A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)
8. Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies
9. Combinations of paclitaxel and etoposide in the treatment of lung cancer
10. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion
11. Sequences of Taxol and cisplatin: A phase I and pharmacologic Study
12. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
13. A randomized study of high versus standard dose carboplatin in patients (pts) with advanced epithelial ovarian cancer (eoc)
14. Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Study Group study
15. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
16. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma
17. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide
18. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung
19. Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum- refractory ovarian cancer
20. The activity of 10-, 14-, 21-day schedules of single-agent etoposide in previously untreated patients with extensive small-cell lung cancer
21. Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, III, IV comparing paclitaxel-cisplatin and paclitaxel-carboplatin
22. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ cell tumors
23. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors
24. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group Study
25. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: Rare events related to DNA-topoisomerase II inhibitors?
26. Balanced chromosome aberrations in leukemia following chemotherapy with DNA-topisomerase II inhibitors
27. Secondary acute myelogenous leukemia following safe exposure to etoposide
28. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
29. Therapy-related leukemia and myelodysplasia following oral administration of etoposide for recurrent breast cancer
30. Risk of leukemia after platinum-based chemotherapy for ovarian cancer
31. A phase I study of topotecan, cisplatin and paclitaxel in newly diagnosed epithelial ovarian cancer: A Gynecologic Oncology Group study
32. Phase 1 trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study